US issues warning over incurable mystery disease

Belgique Nouvelles Nouvelles

US issues warning over incurable mystery disease
Belgique Dernières Nouvelles,Belgique Actualités
  • 📰 MetroUK
  • ⏱ Reading Time:
  • 18 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 11%
  • Publisher: 82%

As many as 450,000 people may have an undiagnosed tick-borne disease that can cause allergic reactions to red meat.

AGS is a potentially life-threatening allergic condition is also known as the red-meat allergy or the tick bite meat allergy.

Common symptoms include hives, itching, swelling, indigestion, diarrhoea, a cough and difficulty breathing. In severe cases, alpha-gal syndrome can also cause anaphylaxis, a life-threatening allergic reaction. The tick usually needs to be attached to the skin for at least 36 hours for the alpha-gal to be transferred into the person’s bloodstream.

Nous avons résumé cette actualité afin que vous puissiez la lire rapidement. Si l'actualité vous intéresse, vous pouvez lire le texte intégral ici. Lire la suite:

MetroUK /  🏆 13. in UK

Belgique Dernières Nouvelles, Belgique Actualités

Similar News:Vous pouvez également lire des articles d'actualité similaires à celui-ci que nous avons collectés auprès d'autres sources d'information.

I had no symptoms and I was young - I never thought I had prostate cancerI had no symptoms and I was young - I never thought I had prostate cancerA CLARKSTON man who discovered he had prostate cancer “just in time” is urging others to be aware of the disease before it is too late.
Lire la suite »

Efficacy of low-dose risperidone in combination with sertraline in first-episode drug-naïve patients with schizophrenia: a randomized controlled open-label study - Journal of Translational MedicineEfficacy of low-dose risperidone in combination with sertraline in first-episode drug-naïve patients with schizophrenia: a randomized controlled open-label study - Journal of Translational MedicineObjective Despite advances in pharmacology, the treatment of schizophrenia (SZ) remains a challenge due to relapse after antipsychotic discontinuation and multiple adverse effects of antipsychotics. We hypothesized that a low dose of risperidone in combination with sertraline would reduce serious adverse effects without decreasing treatment response. This study aimed to examine the efficacy, safety, and tolerability of low-dose risperidone combined with sertraline to reduce risperidone dose and serious adverse effects in first-episode and medication-naive (FEMN) SZ patients. Methods A total of 230 patients with FEMN SZ were randomly assigned to receive low-dose risperidone in combination with sertraline (RS group) or regular-dose risperidone (control group). The Positive and Negative Syndrome Scale (PANSS), Hamilton Depression Rating Scale (HAMD), and Personal and Social Performance Scale (PSP) were assessed at baseline and the end of the first, second, third, and sixth months. In addition, serum prolactin levels and extrapyramidal symptoms were measured at baseline and follow-up. Results Repeated measures ANCOVA showed significant interaction effects of treatment by time on psychotic symptoms, as well as HAMD, PSP scores, prolactin levels, and extrapyramidal symptoms (all p | 0.05). Compared with the control group, the RS group had greater decreases in PANSS total score and its subscores and HAMD score (all p | 0.01) and a greater increase in PSP total score (p | 0.01). Notably, side effects were lower in the RS group relative to the control group. Improvements in HAMD and PANSS total scores, changes in prolactin levels and gender predicted improvements in PSP from baseline to month 6. Conclusions Our study suggests that low-dose risperidone in combination with sertraline was more effective for psychotic symptoms and psychosocial functioning, with significantly fewer adverse effects in patients with FEMN SZ. Trial registration number: ClinicalTrials.gov, NCT0407637
Lire la suite »



Render Time: 2025-04-08 21:35:26